[ad_1]
Kennedy: “We are excited to begin our partnership with Sharps Technology”
West Columbia, South Carolina, November 10, 2022 /PRNewswire/ — Nephron Pharmaceuticals Corporation and Sharps Technology, Inc. today announced that they are developing best practices in innovative manufacturing, product development, customer support and quality as Nephron prepares to launch the InjectEZ component of its expansion. announced an all-new partnership focused on sharing with
Sharps Technology is a medical device and pharmaceutical packaging company that specializes in developing and manufacturing innovative drug delivery systems. Nephron Pharmaceuticals is known to healthcare systems and hospitals nationwide as a leader in manufacturing affordable generic inhalation solutions and suspension products, as well as prefilled sterile syringes, luer lock vials, IV bottles and IV bags. .
InjectEZ is part of a multi-million dollar investment in Nephron. Lexington County, South Carolinafor the past two years. Lou KennedyNephron’s CEO knows that partnerships are key when it comes to launching ambitious initiatives like InjectEZ.
“We are thrilled to begin our partnership with Sharps Technology for a variety of innovative initiatives, including research and development, with the launch of the InjectEZ expansion project,” said Kennedy. Just as we are poised to play a key role in helping those tackling the health crisis, Sharps Technology also provides key solutions to healthcare challenges and we look forward to working with them. I am doing it.”
Sharp’s product line has historically focused on low-waste and ultra-low-waste syringe technology. This allows up to 40% more injections per vial of treatment while incorporating multiple passive safety features. These features protect frontline healthcare workers from life-threatening needlestick injuries and the public from needle reuse. The partnership with Nephron opens an opportunity for Sharps to expand its portfolio and impact the specialized prefillable syringe and drug delivery system market.
“Sharps Technology has identified a unique opportunity to work with an industry leader like Nephron. Robert Hayes, CEO of Sharps Technology. “Through my previous industry experience supporting and working with most of the world’s leading healthcare and pharmaceutical companies, it was easy for me to evaluate Nephron Pharmaceuticals as a potential partner. As a leader and best-in-class partner in the industry, we appreciate and look forward to the opportunity to work together. Bill and Lou Kennedy A leadership team to make this collaboration a success for both companies.”
Sharps Technology brings extensive syringe expertise to Nephron, including specialized pre-filled syringe systems and out-of-the-box processing experience. The prefilled syringe line utilizes the highly automated equipment and controlled environment established by Nephron. These premium pre-filled polymer products are made from the highest quality raw materials with the most innovative technology and comply with USP standards required in the United States. usa As well as EP and JP international standards.
The products to be developed and commercialized will provide solutions to support Nephron’s current fill/finish strategy and pipeline for new drug applications, as well as strategies to support branded medicines and advanced therapeutics, including ophthalmic and biological applications. Promote.
Sharps Technology will also partner with Nephron Pharmaceuticals to develop a pharmaceutical services program designed to support healthcare customers in need of innovative solutions and products to support their business. . The development of this program will help create opportunities for new fill/finish projects for Nephron that utilize innovative packaging solutions developed by Sharps Technology. These new customer projects will drive growth for both companies, and the opportunity to create new technologies to support the healthcare industry will be transformative as Nephron and Sharps work together to navigate a bright future.
Source: Nephron Pharmaceuticals Corporation
[ad_2]
Source link